Loading
Life sciences · Journal article
International Journal of Innovative Technologies in Social Science · September 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
GLP-1 receptor agonists (GLP-1 RAs) have transformed the treatment of type 2 diabetes mellitus (T2DM) and obesity and have recently gained an additional approved indication for metabolic dysfunction-associated steatohepatitis (MASH). Their expanding clinical use has also increased interest in off-label applications and their evolving safety profile. This narrative review summarizes current evidence regarding the off-label use of GLP-1 RAs and evaluates both well-established and emerging adverse effects. A literature search was performed using the PubMed database, and relevant studies addressing approved and off-label applications, efficacy, and safety were qualitatively analyzed. Current evidence suggests that GLP-1 RAs have therapeutic potential beyond approved indications, particularly in polycystic ovary syndrome, antipsychotic-induced weight gain, prediabetes, binge eating disorder, and disorders involving dysregulation of reward-related behavior. The most common adverse effects are gastrointestinal symptoms and gallbladder disorders, whereas emerging safety concerns include weight regain following treatment discontinuation, changes in body composition, hair loss, non-arteritic anterior ischemic optic neuropathy (NAION), and a theoretical risk of medullary thyroid carcinoma in susceptible individuals. Although these findings are promising, the available evidence remains heterogeneous. Further high-quality studies are required to establish the efficacy and long-term safety of off-label applications. Careful patient selection, appropriate monitoring, and integration of pharmacotherapy with lifestyle modification remain essential for optimizing clinical outcomes.